Handelsbanken Fonder Ab Macrogenics Inc Transaction History

Handelsbanken Fonder Ab

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$2.25 - $9.99 $36,900 - $163,836	-16,400 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$15.91 - $21.88 $60,458 - $83,144	3,800 Added 30.16%	16,400 $263,000
Q2 2021 Aug 03, 2021	BUY	$20.49 - $35.63 $84,009 - $146,083	4,100 Added 48.24%	12,600 $338,000
Q1 2021 Apr 29, 2021	BUY	$18.99 - $33.2 $161,415 - $282,200	8,500 New	8,500 $271,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $202M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.